Table 2.
Impact of Therapy on FEV1, in the Studies Included in This Systematic Review
| (1997–2003) BRONCUS* Ref 16 |
(1992–1998) ISOLDE* Ref 6 |
(2000–2005) TORCH* Ref 18 |
(2003–2008) UPLIFT* Ref 11 |
(1986–1994) Lung Health I* Ref 3 | (2011–2015) Zhou et al.* Ref 19 | (2011–2015) SUMMIT* Refs 12 and 20 |
(1992–1994) Copenhagen City Lung Study* Ref 17 | (1994–1999) Lung Health Triamcinolone* Ref 21 | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment arms: placebo/active intervention | Placebo/N-acetylcysteine | Placebo/fluticasone propionate | Placebo/salmeterol/fluticasone propionate/salmeterol + fluticasone propionate/TORCH composite active arm | Placebo/tiotropium | Placebo/ipratropium bromide | Placebo/tiotropium | Placebo/fluticasone furoate/vilanterol/fluticasone furoate + vilanterol/SUMMIT composite active arm | Placebo/budesonide | Placebo/triamcinolone acetonide |
| FEV1 decline in placebo/active (SE), ml | 47 (6)/54 (6) | 59 (4.4)/50 (4.1) | 55.3 (3.2)/42.3 (3.1)/42.3 (3.1)/39.0 (3.0)/41.2 (1.8) | 42 (1)/40 (1) | 52.7 (1.3)/56.2 (1.3) | 51 (6)/29 (5) | 46 (2.5)/38 (2.4)/47 (2.4)/38 (2.4)/41 (1.4) | 49.6/46.0 | 47.0 (3.0)/44.2 (2.9) |
| Treatment difference for each active arm vs. placebo (SE) [95% CI], ml | −8 (9.0) [−25 to 10] | 9 (6.0) [−3 to 20] | 13.0 (4.4) [4.3 to 21.7]/13.0 (4.4) [4.3 to 21.7]/16.3 (4.4) [7.7 to 24.9]/14.1 (3.7) [7.0 to 21.3] | 2 (2) [−2 to 6] | −4 (1.8) | 22 (7.8) [6 to 37] | 8 (3.5) [1 to 14]/−2 (3.4) [−8 to 5]/8 (3.4) [1 to 15]/5 (2.9) [−1 to 11] | 3.1 (8.1) [−12.8 to 19.0] | 2.8 (4.2) |
Definition of abbreviations: BRONCUS = Bronchitis Randomized on NAC Cost-Utility Study; CI = confidence interval; COPD = chronic obstructive pulmonary disease; ISOLDE = Inhaled Steroids in Obstructive Lung Disease in Europe; Ref = reference; SUMMIT = Study to Understand Mortality and Morbidity; TORCH = Toward a Revolution in COPD Health; UPLIFT = Understanding Potential Long-Term Impacts on Function with Tiotropium.
The table presents the rates and the differences between the treatment arms. Statements and numbers in bold reflect the active arms of the study.
*
Date is start of recruitment to study complete.